Dextromethorphan HBr and quinidine sulfate ( DrugBank: Dextromethorphan, Quinidine, Sulfate )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03883581 (ClinicalTrials.gov) | July 25, 2019 | 12/3/2019 | Impact of Nuedexta on Bulbar Physiology and Function in ALS | Impact of Nuedexta on Bulbar Physiology and Function in ALS | Amyotrophic Lateral Sclerosis | Drug: dextromethorphan HBr and quinidine sulfate | University of Florida | Holy Cross Hospital, Florida;ALS Association | Completed | 18 Years | 90 Years | All | 28 | Phase 1/Phase 2 | United States |